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ABSTRACT   Hypertrophic cardiomyopathy (HCM), in contrast to 
common prejudications, has been recognized as the most 
common genetically determined cardiac disease. It is inherited 
with an autosomal dominant pattern and many different 
mutations in numerous genes responsible for the production of 
sarcomere proteins and other regulatory molecules contributing 
to the systolic function of cardiac myocyte have been identified. 
The natural course of the disease is benign in the majority of 
cases and most patients achieve near-normal life expectancy. 
Unfavorable prognosis is established mainly on the basis of 
clinical, morphological and family history data. The genotype 
contributes undoubtedly to the clinical picture. However, the 
existing data do not allow for a consistent genotype-phenotype 
correlation and hence genetic information is not incorporated in 
modern risk assessment clinical tools. In this brief review we 
summarize the recent data on the genetic characterization of 
HCM (Rhythmos 2015;11(1):8-11).   
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phenotype; sudden cardiac death  
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INTRODUCTION  
Once considered a rare and exotic disease, today hyper-
trophic cardiomyopathy (HCM) has been recognized as the 
most common genetic cardiac disease, with a prevalence 
in the general population exceeding 1/500.1 In the past 
decade significant advances have been made regarding its 
genetic screening, imaging modalities and management, 
which have favorably modified the prognosis of the 
disease, and near-normal life expectancy can be achieved 
in many patients with HCM.2 Not surprisingly however, 
certain subtypes of the disease carry a malignant potential 
and a predisposition for severe complications and even 
premature sudden cardiac death (SCD). Genetic testing has 
hopefully been considered as a prognostic factor, in terms 
of its correlation with certain disease subtypes featuring 
particular structural or electrophysiological characteristics 
related to a less benign prognosis. Unfortunately a strong 
relation has not yet been established and there are still gaps 
in our understanding of the molecular pathophysiology. 
Recent evidence 3-33 on this matter is briefly reviewed here.     
EPIDEMIOLOGY  
Hypertrophic cardiomyopathy is a disease reported 
worldwide with similar genotypic, phenotypic, and 
imaging characteristics among different races and nations. 
It affects both genders equally, and in contrast to the 
common perception it is a rather frequent condition, 
affecting 1/500 individuals in the general population. This 
implies that usually the disease is clinically silent and long-
term survival is a common outcome. The clinically evident 
cases may represent more aggressive subforms causing 
limiting symptoms or events which lead to targeted 
investigation and eventually diagnosis. The incidence of 
SCD in children and adolescents with HCM reaches 1-2% 
and is slightly lower (0.5-1%) in older individuals. 4,5   
BASIC PATHOPHYSIOLOGY  
Normal myocardial contraction and relaxation plays a 
cardinal role in the ability of the heart to produce the 
appropriate output to meet the needs of the periphery. In 
HCM, variable mutations of the sarcomere, Z-discs or 
calcium – handling proteins may result in distorted use of 
adenosine triphosphate (ATP) and energy deficiency, 
impaired excitation-contraction coupling and increased 
collagen synthesis and deposition, leading eventually to 
myocardial hypertrophy, disarray and fibrosis. These 
morphological changes cause impaired cardiac relaxation 
initially, full-blown heart failure progressively and 
predispose to atrial and ventricular arrhythmias. 6-8   
GENETICS  
 Hypertrophic cardiomyopathy is a monogenic disease 
inherited with an autosomal dominant pattern. It presents 
variable expressivity and penetrance which increases with 
advancing age. 9-11 However, nearly half of the cases are 
sporadic, with de novo mutations arising in the affected 
persons that do not exist in their parents. Today over 1500 
mutations have been identified as causative and numerous 
genes are implicated, encoding for proteins of the 
sarcomere (thick and thin filaments), Z-discs and Ca+2 –
handling proteins. Most of them are unique to specific 
families and approximately 50% of the genetically 
characterized patients are found to share mutations in the 
thick or thin filament protein genes.12,13 Specifically, 40% 
of HCM cases are caused by mostly missense mutations in 
MYH7 and MYBPC3, which are the two most common 
implicated genes and encode for proteins constituting the 
thick filaments. Mutant thin filament proteins are 
associated with 5-15% of HCM and mutations are detected 
in actin, troponins I, T or C and tropomyosin. Protein 
elements of the Z-discs, which interfere between 
sarcomeres and consist of the platform actin filaments that 
are anchored to, have also been recognized as potential 
sites of mutations, responsible for rare cases of HCM 
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phenotype. Telethonin, vinculin, ankyrin and other 
molecules are relevant. A small percentage of patients may 
also carry mutations in genes encoding Ca+2 –regulating 
proteins, namely phospholamban, calsequestrin 2, 
calreticulin 3 and junctophilin 2. The dysfunctional 
proteins lead to altered calcium regulation and systolic or 
diastolic failure. The genes considered causative are 
summarized in Table 1. Clinically, the disease has by 
definition a standard morphological characteristic, the 
hypertrophy of the left ventricle. However, often the same 
mutation produces different clinical syndromes. 14 This 
suggests that modifying factors also contribute to the final 
phenotype. These factors may be environmental influences 
or the result of the expression of other, still unknown 
genes. Due to the phenotypic variability, a consistent 
correlation between genotype and clinical presentation 
cannot be established. However, some associations are 
more evident than others. Mutations in MYBPC3 present 
in older age, carry less risk for SCD and have a less 
malignant course. MYH7 mutations have unfavorable 
prognosis and are characterized by significant 
hypertrophy. 15 Mutations in TNNT2 are rarely 
accompanied by hypertrophy before adulthood, while this 
is the case in older individuals. 16 Multiple mutations lead 
to early presentation of the disease, severe cardiac 
hypertrophy and increased risk for SCD compared to 
patients with a single mutation. 17 This observation 
suggests a somewhat additive effect of multiple pathologic 
genes when present simultaneously. Furthermore, gene 
polymorphisms in the renin-angiotensin-aldosterone 
system components, androgen receptors and calmodulin 
III may add to the final HCM phenotype. 18-20   
APICAL HYPERTROPHIC CARDIOMYOPATHY 
 An atypical presentation of HCM worldwide, the apical 
type, is relatively common in Japan (15% of cases). 21 
Hypertrophy is localized to the apical region of the left 
ventricle and subsequently it produces no obstructive 
phenomena. It usually exerts characteristic ECG 
abnormalities, namely large negative T waves in many 
leads, mostly anterolateral ones, and, as expected, 
enormous QRS complexes in precordial leads, mainly V4. 
Hypertrophy in the apex cannot be electrically 
counteracted by forces generated in opposite myocardial 
territories because of the presence of the fibrous cardiac 
skeleton in the basal parts. On the contrary, vectorial forces 
generated by hypertrophied lateral, septal, anterior, 
inferior or midventricular territories can be at least partly 
counteracted by those of the opposite wall and thus ECG 
waves are not as impressive in amplitude. 22 In terms of 
genetic identity, apical HCM is frequently sporadic, 
although a familial pattern has been reported, with an 
autosomal dominant inheritance. In most kindreds, the 
identified mutations are not invariably correlated with 
apical hypertrophy but with conventional patterns of the 
disease as well. Mutations reported include troponin I 
Lys183 deletion, Arg21Cys substitution, troponin T 
missense mutations Phe110Ile13 and Arg102Leu, β-
myosin heavy chain Arg243His, Glu497Asp and 
Asp906Gly. However, other mutations, such as cardiac 
actin Glu101Lys and light chain Met149Val missense 
mutations, have been more consistent in their association 
with apical HCM. 23    
Table 1. Known Genes Causing Hypertrophic Cardio-
myopathy (HCM) 
 
Gene Protein Frequency 
Thick filament 
proteins 
MYH7 
MYBPC3 
MYL2 
MYL3 
MYH6 
 
 
β-myosin heavy chain 
myosin binding protein C 
regulatory myosin light chain 
essential myosin light chain 
α-myosin heavy chain 
 
 
15-25% 
15-25% 
rare 
rare 
rare 
Thin filament 
proteins 
TNNT2 
TNNI3 
TNNC1 
TPM1 
ACTC1 
 
 
troponin T 
troponin I 
troponin C 
α-tropomyosin 
α-cardiac actin 1 
 
 
5% 
5% 
rare 
Rare 
rare 
Z-disc proteins 
CSRP3 
TCAP 
VCL 
LDB3 
ACTN2 
MYOZ2 
ANKRD1 
NEXN 
 
muscle LIM protein 
telethonin 
vinculin 
LIM domain binding 3 
α-actinin 2 
myozenin 2 
cardiac ankyrin repeat protein 
nexilin 
 
rare 
rare 
rare 
rare 
rare 
rare 
rare 
rare 
Ca+2- handling 
proteins 
PLN 
CASQ2 
CALR3 
JPH2 
 
 
Phospholamban 
calsequestrin 2 
calreticulin 3 
junctophilin 2 
 
 
rare 
rare 
rare 
rare 
Other 
TTN 
CAV3 
 
Titin 
caveolin 3 
 
rare 
rare   
MIDVENTRICULAR HYPERTROPHIC CARDIO-
MYOPATHY  
Midventricular obstruction in HCM is a rare variant 
especially in non-Asian populations and occurs in only 1% 
of HCM patients. 24 In some cases, apical aneurysm may 
also be evident probably due to the high apical pressure 
arising from the midventricular obstruction, and this 
feature indicates more severe disease. Apical aneurysms 
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develop in 2% of HCM patients and among them, 2/3 have 
midventricular obstruction and the rest have apical 
hypertrophy pattern. 25,26 With regard to the genetic testing, 
midventricular hypertrophy has been associated with 
mutations of the essential or regulatory light chains of 
myosin. Regulatory myosin Ala13Thr and Glu22Lys and 
myosin essential light chain Met149Val are long 
recognized as causative, although they can also produce 
other phenotypic variants. These types of mutation are 
assumed to cause stretch activation response disrupt 
leading to midventricular obstruction. 27,28    
SUDDEN CARDIAC DEATH  
Although not particularly common among HCM 
patients (1-2% annual incidence), SCD is a dramatic 
complication and every effort should be made to avoid it. 
Recently, risk estimation models have been updated and 
offer an important guidance for clinicians. Age, family 
history of SCD, non-sustained ventricular tachycardia, 
syncope, maximum left ventricular wall thickness >30 
mm, left atrial diameter, abnormal exercise blood pressure 
response and left ventricular outflow tract obstruction are 
the major factors clinically appreciated to contribute to 
SCD probability. The new risk model endorsed in the 
recent European guidelines does not take into account 
blood pressure response during stress testing. 29 Genetic 
testing has not been incorporated in risk prediction models. 
In general, patients with sarcomere protein mutations 
present at younger age and report a higher prevalence of 
family history of HCM and SCD than those without a 
mutation. Several studies have reported poor prognosis 
associated with certain mutations. Unfortunately, their 
conclusive strength is limited by the small numbers of 
affected individuals and the scarcity of individual 
mutations. 30-33 Thus, no robust suggestions can be made 
regarding the prognostic power of certain genotypes.   
CONCLUSION  
Without ignoring the risk that such a diagnosis poses 
upon an individual’s life, HCM is now regarded as a more 
frequent disease and with an overall more favorable natural 
history than a clinician would reckon. Significant advances 
have been made in the last decade concerning the genetic 
analysis of affected individuals and their families. Over 
1500 mutations have been identified in >20 genes 
encoding for structural or functional proteins of the 
sarcomere. However, most of these mutations usually do 
not produce a specific phenotype, and many are found 
uniquely in certain families. Hence, although ambitious 
and deterministic from a philosophical point of view, the 
effort to fully characterize a patient by genotype has 
proven elusive, which is why contemporary risk 
assessment algorithms do not include genetic information. 
More research is needed in this field in order to elucidate 
the complex regulatory mechanisms which govern the 
translation of a certain genetic identity into the final 
clinical phenotype.    
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